Legal & General Group Plc Has $346,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Legal & General Group Plc decreased its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 63.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,823 shares of the biotechnology company's stock after selling 76,793 shares during the quarter. Legal & General Group Plc owned approximately 0.09% of REGENXBIO worth $346,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock valued at $27,000 after buying an additional 2,510 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in REGENXBIO in the 4th quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of REGENXBIO in the 4th quarter worth approximately $79,000. Teacher Retirement System of Texas grew its holdings in shares of REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company's stock worth $97,000 after purchasing an additional 2,088 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new stake in shares of REGENXBIO during the fourth quarter valued at approximately $97,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Chardan Capital reiterated a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target for the company. Leerink Partners set a $24.00 price objective on REGENXBIO in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group lowered their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX traded up $0.57 during trading on Friday, reaching $10.40. The stock had a trading volume of 1,015,830 shares, compared to its average volume of 822,267. The stock has a market capitalization of $521.22 million, a PE ratio of -2.07 and a beta of 1.11. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $17.52. The business's 50-day moving average price is $7.16 and its 200 day moving average price is $8.09.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.